Systemic glucocorticoids confound SARS–CoV‐2 acquisition or even clinical outcomes in patients with autoimmune disease treated with biologics: comment on the article by Simon et al

Systemic glucocorticoids confound SARS–CoV‐2 acquisition or even clinical outcomes in patients with autoimmune disease treated with biologics: comment on the article by Simon et al

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2022-12, Vol.74 (12), p.2042-2043
Hauptverfasser: Niu, Man‐Man, Jiang, Qi, Zhang, Yan‐Fang, Li, Dao‐Ting, Yang, Qian, Hu, Peng
Format: Artikel
Sprache:eng
Schlagworte:
Autoimmune diseases
Autoimmune Diseases - drug therapy
Biological Products - therapeutic use
COVID-19
Glucocorticoids
Glucocorticoids - therapeutic use
Humans
Medical treatment
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2043
container_issue 12
container_start_page 2042
container_title Arthritis & rheumatology (Hoboken, N.J.)
container_volume 74
creator Niu, Man‐Man
Jiang, Qi
Zhang, Yan‐Fang
Li, Dao‐Ting
Yang, Qian
Hu, Peng
description
doi_str_mv 10.1002/art.42303
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2688568921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2688568921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3483-6d54f23f82fb9592331391626ebf0c621ea2a2b8c48f6478b76ce75836a79f93</originalsourceid><addsrcrecordid>eNp1kUtqHDEQhpuQEBvHi1wgCLJJFmPr0a2WshuGvMAQ8AzZNmp1tS3TksZ62MzORwj4Mj6PTxJN2s4ikNqoKH36_xJ_Vb0l-IRgTE9VSCc1ZZi9qA4po3zRUNy8fO6JJAfVcYxXuJRsMcfN6-qANYJIgdvD6mG9iwms0ehiytprH5LR3gwRae9Gn92A1svz9ePd_cr_fLz7RZHS19lEk4x3yAcEN-CQnowzWk3I56S9hYiMQ1uVDLgU0a1Jl0jl5I212QEaTAQVAaUAKsEw3_fGT_7C6PipOFtbHqJikC4Bqf1KE6B-h9bGliEkpKY31atRTRGOn86javPl82b1bXH24-v31fJsoVkt2IIPTT1SNgo69rKRlDHCJOGUQz9izSkBRRXtha7FyOtW9C3X0DaCcdXKUbKj6sMsuw3-OkNMnTVRwzQpBz7HjnIhGi4kJQV9_w965XNwZbmOtk3NqJT1nvo4Uzr4GAOM3TYYq8KuI7jbB9qV_3Z_Ai3suyfF3FsY_pLP8RXgdAZuzQS7_yt1y_PNLPkbJpWuSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754329941</pqid></control><display><type>article</type><title>Systemic glucocorticoids confound SARS–CoV‐2 acquisition or even clinical outcomes in patients with autoimmune disease treated with biologics: comment on the article by Simon et al</title><source>MEDLINE</source><source>Wiley Online Library eJournals</source><source>Alma/SFX Local Collection</source><creator>Niu, Man‐Man ; Jiang, Qi ; Zhang, Yan‐Fang ; Li, Dao‐Ting ; Yang, Qian ; Hu, Peng</creator><creatorcontrib>Niu, Man‐Man ; Jiang, Qi ; Zhang, Yan‐Fang ; Li, Dao‐Ting ; Yang, Qian ; Hu, Peng</creatorcontrib><identifier>ISSN: 2326-5191</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.42303</identifier><identifier>PMID: 35819807</identifier><language>eng</language><publisher>Boston, USA: Wiley Periodicals, Inc</publisher><subject>Autoimmune diseases ; Autoimmune Diseases - drug therapy ; Biological Products - therapeutic use ; COVID-19 ; Glucocorticoids ; Glucocorticoids - therapeutic use ; Humans ; Medical treatment ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Arthritis &amp; rheumatology (Hoboken, N.J.), 2022-12, Vol.74 (12), p.2042-2043</ispartof><rights>2022 American College of Rheumatology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3483-6d54f23f82fb9592331391626ebf0c621ea2a2b8c48f6478b76ce75836a79f93</cites><orcidid>0000-0002-2144-9806 ; 0000-0003-0959-5955</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.42303$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.42303$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35819807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niu, Man‐Man</creatorcontrib><creatorcontrib>Jiang, Qi</creatorcontrib><creatorcontrib>Zhang, Yan‐Fang</creatorcontrib><creatorcontrib>Li, Dao‐Ting</creatorcontrib><creatorcontrib>Yang, Qian</creatorcontrib><creatorcontrib>Hu, Peng</creatorcontrib><title>Systemic glucocorticoids confound SARS–CoV‐2 acquisition or even clinical outcomes in patients with autoimmune disease treated with biologics: comment on the article by Simon et al</title><title>Arthritis &amp; rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheumatol</addtitle><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Biological Products - therapeutic use</subject><subject>COVID-19</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Medical treatment</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>2326-5191</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtqHDEQhpuQEBvHi1wgCLJJFmPr0a2WshuGvMAQ8AzZNmp1tS3TksZ62MzORwj4Mj6PTxJN2s4ikNqoKH36_xJ_Vb0l-IRgTE9VSCc1ZZi9qA4po3zRUNy8fO6JJAfVcYxXuJRsMcfN6-qANYJIgdvD6mG9iwms0ehiytprH5LR3gwRae9Gn92A1svz9ePd_cr_fLz7RZHS19lEk4x3yAcEN-CQnowzWk3I56S9hYiMQ1uVDLgU0a1Jl0jl5I212QEaTAQVAaUAKsEw3_fGT_7C6PipOFtbHqJikC4Bqf1KE6B-h9bGliEkpKY31atRTRGOn86javPl82b1bXH24-v31fJsoVkt2IIPTT1SNgo69rKRlDHCJOGUQz9izSkBRRXtha7FyOtW9C3X0DaCcdXKUbKj6sMsuw3-OkNMnTVRwzQpBz7HjnIhGi4kJQV9_w965XNwZbmOtk3NqJT1nvo4Uzr4GAOM3TYYq8KuI7jbB9qV_3Z_Ai3suyfF3FsY_pLP8RXgdAZuzQS7_yt1y_PNLPkbJpWuSQ</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Niu, Man‐Man</creator><creator>Jiang, Qi</creator><creator>Zhang, Yan‐Fang</creator><creator>Li, Dao‐Ting</creator><creator>Yang, Qian</creator><creator>Hu, Peng</creator><general>Wiley Periodicals, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2144-9806</orcidid><orcidid>https://orcid.org/0000-0003-0959-5955</orcidid></search><sort><creationdate>202212</creationdate><title>Systemic glucocorticoids confound SARS–CoV‐2 acquisition or even clinical outcomes in patients with autoimmune disease treated with biologics: comment on the article by Simon et al</title><author>Niu, Man‐Man ; Jiang, Qi ; Zhang, Yan‐Fang ; Li, Dao‐Ting ; Yang, Qian ; Hu, Peng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3483-6d54f23f82fb9592331391626ebf0c621ea2a2b8c48f6478b76ce75836a79f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Biological Products - therapeutic use</topic><topic>COVID-19</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Medical treatment</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niu, Man‐Man</creatorcontrib><creatorcontrib>Jiang, Qi</creatorcontrib><creatorcontrib>Zhang, Yan‐Fang</creatorcontrib><creatorcontrib>Li, Dao‐Ting</creatorcontrib><creatorcontrib>Yang, Qian</creatorcontrib><creatorcontrib>Hu, Peng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niu, Man‐Man</au><au>Jiang, Qi</au><au>Zhang, Yan‐Fang</au><au>Li, Dao‐Ting</au><au>Yang, Qian</au><au>Hu, Peng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic glucocorticoids confound SARS–CoV‐2 acquisition or even clinical outcomes in patients with autoimmune disease treated with biologics: comment on the article by Simon et al</atitle><jtitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheumatol</addtitle><date>2022-12</date><risdate>2022</risdate><volume>74</volume><issue>12</issue><spage>2042</spage><epage>2043</epage><pages>2042-2043</pages><issn>2326-5191</issn><eissn>2326-5205</eissn><cop>Boston, USA</cop><pub>Wiley Periodicals, Inc</pub><pmid>35819807</pmid><doi>10.1002/art.42303</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-2144-9806</orcidid><orcidid>https://orcid.org/0000-0003-0959-5955</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2326-5191
ispartof Arthritis & rheumatology (Hoboken, N.J.), 2022-12, Vol.74 (12), p.2042-2043
issn 2326-5191
2326-5205
language eng
recordid cdi_proquest_miscellaneous_2688568921
source MEDLINE; Wiley Online Library eJournals; Alma/SFX Local Collection
subjects Autoimmune diseases
Autoimmune Diseases - drug therapy
Biological Products - therapeutic use
COVID-19
Glucocorticoids
Glucocorticoids - therapeutic use
Humans
Medical treatment
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
title Systemic glucocorticoids confound SARS–CoV‐2 acquisition or even clinical outcomes in patients with autoimmune disease treated with biologics: comment on the article by Simon et al
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A24%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20glucocorticoids%20confound%20SARS%E2%80%93CoV%E2%80%902%20acquisition%20or%20even%20clinical%20outcomes%20in%20patients%20with%20autoimmune%20disease%20treated%20with%20biologics:%20comment%20on%20the%20article%20by%20Simon%20et%20al&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Niu,%20Man%E2%80%90Man&rft.date=2022-12&rft.volume=74&rft.issue=12&rft.spage=2042&rft.epage=2043&rft.pages=2042-2043&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.42303&rft_dat=%3Cproquest_cross%3E2688568921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2754329941&rft_id=info:pmid/35819807&rfr_iscdi=true